Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging

Clinical Trial Details

This clinical trial is for men and women with high-grade gliomas. Glucose (sugar) is thought to be a contributor to tumor growth. The ketogenic diet (a high fat, low carbohydrate diet) and metformin (a drug approved by the Food and Drug Administration to treat type 2 diabetes) are both known to lower blood glucose levels. 
The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin and whether maintaining and the diet with metformin will have any effect on your tumor. Participants will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key Eligibility: 
  • Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas.
  • Participants must not have recurrent disease, must not have been exposed to bevacizumab, and cannot be taking insulin or other oral hypoglycemic.
  • Detailed eligibility reviewed when you contact the study team. 

Study contact by location

Upper East Side - Manhattan


Victoria Dai
(212) 746-2225

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group